<DOC>
	<DOCNO>NCT00464074</DOCNO>
	<brief_summary>This study aim study effect TYSABRI® treatment fatigue cognition patient relapse form MS .</brief_summary>
	<brief_title>Evaluation Natalizumab thE Relief MS Associated FatiGue</brief_title>
	<detailed_description>TYSABRI® treatment already demonstrate significant improvement quality life ( QoL ) patient MS . In particular , TYSABRI® add-on treatment interferon beta-1a demonstrate improvement fatigue measure Modified Fatigue Impact Scale ( MFIS ) . Both patient neurologist report patient experienced significant improvement fatigue shortly initiate TYSABRI® treatment . Fatigue common disabling symptom MS. Further , evidence fatigue contributes cognitive difficulty patient MS . This study aim study effect TYSABRI® treatment fatigue cognition patient relapse form MS . The primary objective study determine effect TYSABRI® treatment fatigue subject relapse form MS measure change patient-reported Visual Analog Scale Fatigue ( VAS-F ) . Primary endpoint change follow : 1 . Visual Analog Scale Fatigue ( VAS-F ) three month initiate treatment TYSABRI® . Secondary objective measure change patient-reported Modified Fatigue Impact Scale ( MFIS ) Fatigue Severity Scale ( FSS ) . Secondary endpoint change follow : 1 . Modified Fatigue Impact Scale ( MFIS ) 2 . Fatigue Severity Scale ( FSS ) The tertiary objective study explore effect TYSABRI® treatment cognition assess change Automated Neuropsychology Assessment Metrics ( ANAM ) . Tertiary endpoint change Automated Neuropsychology Assessment Metrics ( ANAM ) consisting : - Traditional Continuous Performance Test - Running Memory Continuous Performance Test - Simple Response Time - Procedural Response Time - Coding Substitution - Mathematics - Logical Relations - Matching-to-Sample - Stanford Sleepiness Scale</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>1 . Diagnosis relapse form MS. 2 . Patients inadequate response unable tolerate alternate MS therapy . 3 . Patient must enrol TOUCH prescribe program . 4 . Recent MRI part TOUCH prescribing program . 5 . Patient must 18 55 year age , inclusive . 6 . EDSS 0 5.5 , inclusive . 7 . Able provide write informed consent . 8 . Capable complete fatigue ( MFIS , FSS , VASF ) cognition ( ANAM ) session . 9 . A baseline VASF average score &gt; 60 . 10 . Patient must naÃƒve TYSABRI® treatment . 1 . Patients enrol TOUCH prescribe program . 2 . History presence progressive multifocal leukoencephalopathy ( PML ) . 3 . Diagnosis primary progressive MS ( PPMS ) secondary progressive MS ( SPMS ) without relapse . 4 . Immunocompromised judgment investigator . 5 . Allergy hypersensitivity TYSABRI® . 6 . Prior history current presence clinically significant medical illness laboratory abnormality , include significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , and/or major disease , , opinion investigator , would preclude administration TYSABRI® . 7 . Women pregnant , breast feeding , plan become pregnant woman postmenopausal surgically sterile , unwilling practice contraception . 8 . A baseline average VASF score &lt; 60 . 9 . Problems upper extremity dexterity could preclude usage computer mouse . 10 . With educational completion 8th grade school equivalent nonfluent English . 11 . Any reason , opinion Investigator and/or Sponsor , patient determine suitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>fatigue</keyword>
	<keyword>Tysabri</keyword>
	<keyword>cognition</keyword>
</DOC>